Drug Therapy in Obese Adolescents

Zinat Salem; Mohsen Rezaeian

Zahedan Journal of Research in Medical Sciences

The Official Journal of Zahedan University of Medical Sciences

Current Issue All Issues In Press Articles Accepted Manuscripts Search

Journal Information Boards and Committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Contact Us Support Reviewer and AE Registration Form

APC

Authors Guide Submit Manuscript

Drug Therapy in Obese Adolescents

Author(s):

Zinat Salem^1,*,

Mohsen Rezaeian²

1Department of Social Medicine, Occupational Environment Research Center, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan,Iran

2Department of Epidemiology, Occupational Environment Research Center, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

Zahedan Journal of Research in Medical Sciences:Vol. 15, issue 3; e93051

Published online:Oct 30, 2012

Article type:Review Article

Received:Dec 19, 2010

Accepted:Mar 25, 2011

How to Cite:Zinat SalemMohsen RezaeianDrug Therapy in Obese Adolescents.Zahedan J Res Med Sci.15(3):e93051.

Abstract

Background : The behavior and dietary treatments are not so successful for extremely obese adolescents. Therefore, using drugs to treat extremely obese children and adolescents are among the modern approaches. This research aims to study the pharmaceutical interventions performed for treatment of obese children.
Materials and Methods : The strategy of research was using of key words ‘obesity’, ‘adolescence’, ‘treatment’ and ‘anti-obesity drugs’ were searched in websites of PubMed, Iranian Medical Digital Library, SID, Iran Medex, Magiran. This study reviewed all the available published papers in English and Farsi languages during 2000-2010. The Criteria for exclusion was The papers that had been published on interventions and treatment of eating disorders, type II diabetes or the obesity caused by the secondary syndromes.
Results : Twelve papers were found as short-term clinical trials and/or long-term follow-ups. In these studies, the positive effects of ‘sibutramine’ in some studies are shown although some other side effects are reported as well. A significant weight-loss had been reported on ‘orlistat’ medicine, but digestive complications had been observed as well. None of the studies had followed up patients for more than one year. Apparently, ‘Metformin’ requires further studies.
Conclusion : The FDA has only approved ‘sibutramine’ and ‘orlistat’ drugs. But side effects of long-term these drugs have already been unknown. However, it seems that ‘orlistat’ is applied for ≥12-year-old children and ‘sibutramine’ for ≥ 16-year-old children.

Keywords

Fulltext

The full text of this article is available on the PDF file.

References

1.
The References of this article are available on the PDF file.

comments